Skip to content

Efficacy of Unani drugs in Obesity

Efficacy of Sundrus and Kundur along with Sikanjabeen Sada in Stage 1 Obesity - A Comparative Randomised Controlled Clinical Trial - ESKSSO

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/032025
Enrollment
30
Registered
2021-03-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E668- Other obesity

Interventions

Intervention1: Sundrus (Trachylobium hornemannianum): Given along with Sikanjabeen Sada in Capsule form 3gm in two divided doses Intervention2: Sundrus (Trachylobium hornemannianum Hayne) along with S

Sponsors

National Institute of Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients having Body Mass Index 25-29.9 kg/m2 2. Patients with or without mild to moderate stage 1 obesity related complications such as -Hypertriglyceridemia with fasting serum triglyceride level 150-400 mg/dl -Prediabetes (Hyperglycemia) with FBS -Prehypertension with blood pressure 3. Patients who will give consent and are able to do follow up

Exclusion criteria

Exclusion criteria: 1. Patients below 20 and above 50 years 2. Patients having BMI 29.9 kg/m2 3. Fasting serum triglyceride level >400 mg/dl 4. Blood pressure >=140/90 mm Hg or treated with diuretics and ACE inhibitors 5. Fasting blood sugar >=126 mg/dL, PPBS >=200 mg/dL or treated with oral hypoglycaemic agents or insulin 6. Patient with hypothyroidism, any other serious systemic illness or known case of IHD 7. Psychiatric disorders including major depression, schizophrenia, bulimia, alcohol abuse or substance abuse 8. Use of drugs, herbs or supplements known to significantly affect body weight (anti-obesity agents, anti-depressants, antipsychotics, anti-epileptic drugs, glucocorticoids, laxatives, oral contraceptives, female hormones etc.) within the past 3 months 9. History of bariatric surgery or abdominal adhesion after surgery 10. Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
BMI, WC, WHRTimepoint: 0th, 20th, 40th and 60th day

Secondary

MeasureTime frame
Improvement in Quality of lifeTimepoint: 0th, 20th, 40th and 60th day;Stage 1 Obesity related complicationsTimepoint: 0th and 60th day

Countries

India

Contacts

Public ContactFatima Rafique

National Institute of Unani Medicine

draafreensq0811@gmail.com8355868300

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026